Matt Phipps
Stock Analyst at William Blair
(n/a)
# 3,554
Out of 4,479 analysts
12
Total ratings
n/a
Success rate
-78.99%
Average return
Main Sectors:
Top Industries:
12 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CGEM Cullinan Oncology | Initiates: Outperform | n/a | $16.31 | - | 1 | Apr 15, 2024 | |
| BMY Bristol-Myers Squibb Company | Downgrades: Market Perform | n/a | $40.45 | - | 1 | Oct 27, 2023 | |
| KZR Kezar Life Sciences | Downgrades: Market Perform | n/a | $0.57 | - | 1 | Mar 16, 2023 | |
| JANX Janux Therapeutics | Initiates: Outperform | n/a | $39.30 | - | 1 | Nov 14, 2022 | |
| GMAB Genmab | Initiates: Market Perform | n/a | $24.90 | - | 1 | Nov 14, 2022 | |
| ALRN Aileron Therapeutics | Downgrades: Market Perform | n/a | $2.76 | - | 1 | Jun 29, 2022 | |
| INKT MiNK Therapeutics | Initiates: Outperform | n/a | $0.89 | - | 1 | Nov 9, 2021 | |
| CALA Calithera Biosciences | Downgrades: Market Perform | n/a | $0.01 | - | 1 | Nov 5, 2021 | |
| TPST Tempest Therapeutics | Initiates: Outperform | n/a | $2.12 | - | 1 | Oct 21, 2021 | |
| JSPR Jasper Therapeutics | Initiates: Outperform | n/a | $22.78 | - | 1 | Oct 21, 2021 | |
| BIIB Biogen | Upgrades: Outperform | n/a | $228.82 | - | 1 | Jun 8, 2021 | |
| MRUS Merus | Initiates: Outperform | n/a | $53.09 | - | 1 | Apr 8, 2021 |
Cullinan Oncology
Apr 15, 2024
Initiates: Outperform
Price Target: n/a
Current: $16.31
Upside: -
Bristol-Myers Squibb Company
Oct 27, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $40.45
Upside: -
Kezar Life Sciences
Mar 16, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $0.57
Upside: -
Janux Therapeutics
Nov 14, 2022
Initiates: Outperform
Price Target: n/a
Current: $39.30
Upside: -
Genmab
Nov 14, 2022
Initiates: Market Perform
Price Target: n/a
Current: $24.90
Upside: -
Aileron Therapeutics
Jun 29, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $2.76
Upside: -
MiNK Therapeutics
Nov 9, 2021
Initiates: Outperform
Price Target: n/a
Current: $0.89
Upside: -
Calithera Biosciences
Nov 5, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $0.01
Upside: -
Tempest Therapeutics
Oct 21, 2021
Initiates: Outperform
Price Target: n/a
Current: $2.12
Upside: -
Jasper Therapeutics
Oct 21, 2021
Initiates: Outperform
Price Target: n/a
Current: $22.78
Upside: -
Biogen
Jun 8, 2021
Upgrades: Outperform
Price Target: n/a
Current: $228.82
Upside: -
Merus
Apr 8, 2021
Initiates: Outperform
Price Target: n/a
Current: $53.09
Upside: -